If your research interest is focused on the identification of cell signalling pathways and protein phosphorylation profiles, the comprehensive Phospho Explorer Array may be of great help to you, measuring changes in phosphorylation status in more than 1000 targets at once. I invite you to take a look at the technology and its benefits, after which I’ve included some publications in 2018 to give you an idea of how other researchers have used this array and how it helped them generate meaningful data in their phosphorylation studies.

Antibody generation raises a number of questions… what is the difference between their classes, forms and types? And how do recombinant monoclonal antibodies (rAbs) overcome the drawbacks of classical monoclonal antibodies (mAbs)?

Monoclonal antibodies are ubiquitous in biomedical research and medicine. They are used to fight, diagnose and research disease and to develop and test new drugs. The antibodies are divided in 5 classes or isotypes, several subtypes and forms and can be generated in vivo or in vitro.

In this short article, my aim is to define what an antibody is, to highlight the differences between a hybridoma monoclonal antibody and a recombinant monoclonal antibody and to point out how rAbs bring solutions to the classical drawbacks of mAbs.

As they say, a good picture is worth a thousand words. That’s to say that I’ll have to keep the introduction short in this post (!) to let you know about this interesting map from Boster Bio summarizing the allergic response pathway. I’ll take this opportunity to mention a few related immunoassays that may help you deciphering this pathway in your own study!

Personalized treatment for cancer reached a new milestone with the FDA approval of CAR T-cells for treatment of leukemia and lymphoma.  There is now rapid growth in research on the therapeutic uses of CAR T-cells.

To help researchers develop efficient CAR T-cells, we aim to provide many innovative solutions, such as recombinant cell line expressing cancer antigens, or recombinant versions of these antigens. Developed by BPS Bioscience, these products will help scientists to more precisely monitor the effectiveness of the engineered CAR T to detect and bind to a specific cancer antigen.